三生国健药业（上海）股份有限公司 关于核心技术人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"）下 属子公司核心技术人员翁志兵先生因个人原因申请辞去其在全资子 公司担任的所有职务，离职后翁志兵不再担任公司任何职务。截至本 公告日，翁志兵先生直接持有公司股份 30 股。 翁志兵先生工作期间作为发明人申请的相关专利所有权均归 属于公司，亦不存在涉及职务成果、知识产权相关的纠纷或潜在纠纷 的情形，翁志兵先生的离职不影响公司专利等知识产权的完整性。 证券代码：688336 证券简称：三生国健 公告编号：2025-064 翁志兵先生在职期间负责的工作已妥善交接，其离职不会影响 公司核心技术的完整性，不会对公司生产经营带来实质性影响，不会 对公司研发实力、核心竞争力和产品创新产生不利影响。 一、核心技术人员离职的具体情况 公司近日收到核心技术人员翁志兵先生的书面辞职报告，翁志兵 先生因个人原因申请辞去在公司全资子公司担任的所有职务，辞职后 翁志兵先生不再 ...

三生国健公告，核心技术人员翁志兵因个人原因申请辞去在全资子公司担任的所有职务，离职后不再担 任公司任何职务。截至公告日，翁志兵持有公司股份30股。其在职期间负责的工作已交接，离职不影响 公司专利等知识产权的完整性，不会对生产经营、研发实力、核心竞争力和产品创新产生不利影响。 ...

智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临 床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为 未来License-out项目的重点方向。我国创新药企业已从高投入低产出的研发探索期过渡到了管线密集收 获期，与此同时商保的发展有望让原先的创新药"单一"支付向多元支付转型。此外，医疗器械2025年招 采端持续复苏，关注设备更新政策与资金落地持续驱动需求释放。 东方财富证券主要观点如下： 标的方面 创新药板块建议关注百济神州(06160)、恒瑞医药(01276)、中国生物制药(01177)、三生制药(01530)/三生 国健(688336.SH)、石药集团(01093)等。医疗器械板块：1）内需修复：建议关注迈瑞医疗(300760.SZ)、 联影医疗(688271.SH)、开立医疗(300633.SZ)、澳华内镜(688212.SH)等；2）出海兑现：建议关注海泰新 光(688677.SH)、新产业(300832.SZ)等；3）脑机接口：建议关注诚益通(300430.SZ)、伟思医疗 (688580.SH)等。 ...

证券之星消息，12月15日，医疗健康R（480016）指数报收于7247.38点，跌1.42%，成交212.07亿元，换 手率0.7%。当日该指数成份股中，上涨的有12家，同仁堂以2.38%的涨幅领涨，下跌的有35家，泽璟制 药以8.6%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sh688266 | 演唱制药 | -- | 100.00 | -8.60% | 264.71 | 医药生物 | | sh688336 | 三生国健 | -- | 60.70 | -5.83% | 374.39 | 医药生物 | | sh688192 | 迪哲医药 | -- | 58.54 | -5.73% | 269.98 | 医药生物 | | sh688520 | 神州细胞 | | 44.65 | -4.08% C | 198.84 | 医药生物 | | sz002294 | 信立泰 | -- | 56.50 | -3 ...

Company Summary - Yipinhong (300723) experienced a sudden 20% drop in stock price despite a favorable announcement regarding its product Qinxiangqing oral solution being approved as a national second-level protected traditional Chinese medicine [1][3] - The company’s stake in the US company Arthrosi received a buyout offer with a total transaction value of up to $1.5 billion (approximately 10.6 billion RMB), but the market's expectations shifted from a business development (BD) perspective to a direct sale, leading to a decline in stock price [1][2] - Yipinhong's stock had previously surged over 500% from September last year to July this year, but has since halved in value, indicating a potential market correction [2] Industry Summary - The overall performance of the innovative drug sector was negatively impacted, with the Hong Kong innovative drug index dropping over 2% and several companies experiencing declines of more than 5% [4] - The innovative drug business development (BD) transactions in China have seen explosive growth this year, with projections suggesting that by the end of 2025, the transaction volume will exceed $100 billion, accounting for nearly 50% of global transactions [4] - The Chinese innovative drug market is expected to grow from approximately 819.8 billion RMB in 2020 to 1.14 trillion RMB by 2024, with a compound annual growth rate of 8.53%, and is projected to surpass 1.22 trillion RMB by 2025 [5]

证券代码： 688336 证券简称：三生国健 公告编号：2025-063 三生国健药业（上海）股份有限公司 关于收到实际控制人《解除<一致行动协议>的通知 函》的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本事项系三生国健药业（上海）股份有限公司（以下简称"公 司"）的实际控制人 LOU JING 解除与 TAN BO、苏冬梅、黄斌签署的 《一致行动协议》。 本次解除一致行动关系不会导致公司控股股东、实际控制人发 生变化，亦不会影响公司治理结构和持续经营。 公司于近日收到公司实际控制人 LOU JING 先生出具的《解除< 一致行动协议>的通知函》，现将有关情况公告如下： 一、原《一致行动协议》签署情况 根据 LOU JING 与 TAN BO、苏冬梅、黄斌签署的《一致行动协议》， 各方确认，自三生制药在香港联交所上市之日起，TAN BO、苏冬梅、 黄斌及其间接持有或控制的实体在三生制药董事会及股东大会审议 相关事项时，均与 LOU JING 在事实上保持了一致意见及一致行动， 并承诺协议签 ...

Core Viewpoint - Hair loss anxiety has become a significant concern for approximately 340 million people in China, leading to a burgeoning market for hair health management products, projected to reach 52.7 billion yuan by 2024, up from 19.8 billion yuan in 2018, marking a 2.6-fold increase [6][9]. Group 1: Market Dynamics - The topic of hair loss has garnered over 2.86 billion views on social media platforms, indicating a strong consumer interest and anxiety surrounding the issue [6]. - The number of hair loss patients in China has surged from 270 million in 2018 to 340 million in 2024, with a compound annual growth rate of 3.8%, and over 60% of this demographic is under 35 years old [9][10]. - The hair health management market is expected to expand to 171.4 billion yuan by 2035, with the hair loss treatment segment growing from 500 million yuan in 2018 to 3.5 billion yuan in 2024, a sevenfold increase over seven years [13]. Group 2: Company Overview - Mandi International, a leading player in the hair loss treatment sector, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to become the first public company focused on hair loss prevention [6][8]. - The company has maintained a dominant market share, with its products accounting for approximately 92% of total revenue from 2022 to the first half of 2025 [22]. - Mandi's revenue has shown significant growth, with figures reaching 982 million yuan in 2022, 1.228 billion yuan in 2023, and 1.455 billion yuan in 2024, alongside a net profit of 202 million yuan, 341 million yuan, and 390 million yuan respectively [18][20]. Group 3: Financial Performance - Mandi International's gross margin has consistently remained above 80%, with net profit margins between 20% and 30%, comparable to high-margin industries like liquor [18]. - The company has engaged in a "clearance dividend" strategy, distributing 1.42 billion yuan in dividends from 2022 to the first half of 2025, which has significantly reduced its cash reserves from 1.127 billion yuan at the end of 2024 to 110 million yuan in the first half of 2025 [24][25]. - The company's financial ratios indicate potential liquidity issues, with the current ratio dropping from 4.3 in 2024 to 1.0 in the first half of 2025, and the quick ratio falling below 1.0 to 0.8 [26]. Group 4: Competitive Landscape - Mandi International faces increasing competition as several companies are entering the hair loss treatment market, leveraging lower prices and aggressive marketing strategies [26]. - The concentration of suppliers and customers poses risks, with the top five suppliers accounting for 75.6% of total purchases and the top five customers contributing 62.6% of revenue [24]. - The company’s reliance on a single product line, particularly the minoxidil series, raises concerns about revenue stability in the face of market competition and potential patent expirations [22][24]. Group 5: Future Outlook - Mandi International's journey from launching its first minoxidil product in 2001 to its upcoming IPO reflects the growth of the hair loss treatment market driven by consumer anxiety [27][29]. - The company must demonstrate its long-term value beyond just strong sales of its hair loss products to succeed in the capital market [29].

Group 1: Xiaomi's AI Education Rumors - Xiaomi responded to rumors about entering the AI education sector, clarifying that recent job postings related to AI education are primarily for products like the Redmi Pad 2 and MiTu children's watch, not for launching educational programs [2] Group 2: Alibaba Cloud's New Product Launch - Alibaba Cloud launched AgentRun, a one-stop AI infrastructure platform that integrates Serverless features with AI-native application scenarios, helping enterprises optimize costs and efficiency, with an average Total Cost of Ownership (TCO) reduction of 60% [3] Group 3: Second-Hand Market Trends - The price of the Nubia M153 AI phone has surged in the second-hand market, with listings on platforms like Xianyu ranging from 3,999 to 4,999 yuan, and some reaching as high as 36,000 yuan due to the inability to purchase through official channels [4] - The Quark AI glasses S1 are sold out on major e-commerce platforms, with second-hand prices reaching 4,000 to 5,000 yuan, indicating high demand [7] Group 4: Apple’s New Delivery Service - Apple has launched a free three-hour delivery service for select products in mainland China, with free shipping available for iPhones, iPads, Apple Watches, MacBook Pros, MacBook Airs, and AirPods for certain orders [5] Group 5: Investment and Financial Updates - Century Huatong announced that its indirect investment in Moer Thread is expected to generate a net profit of 640 million yuan in Q4 2023, accounting for approximately 53% of the company's audited net profit for 2024 [7] - Taiji Industry's subsidiary plans to transfer up to 85 million USD in receivables to a bank, ensuring the receivables are genuine and valid [8] - OPPO signed a global patent licensing agreement with Audi, allowing the use of its cellular communication patents, including 5G, to enhance Audi's connected vehicle products [9] Group 6: Corporate Developments - Qualcomm announced the acquisition of Ventana Micro Systems to enhance its RISC-V CPU capabilities, marking a significant step in its commitment to RISC-V standards [11] - Haiguang Information stated that despite the termination of a merger, it will continue to collaborate with Zhongke Shuguang in areas like intelligent computing and data center solutions [12] - Yun Tian Li Fei is upgrading its Nova 500 series to a new GPNPU architecture, aiming to improve compatibility, performance, and efficiency for AI inference applications [13] Group 7: Capital Market Activities - Lens Technology plans to acquire 100% of PMG International Co., Ltd., which may allow it to enter NVIDIA's supply chain and enhance its capabilities in AI hardware infrastructure [14][15] - Muxi Co. reported that over 20,000 shares were abandoned by investors during its recent issuance, with the underwriting firm covering the abandoned shares [16] - Celerity Technology received approval from the China Securities Regulatory Commission for its overseas listing of up to 130,204,100 shares on the Hong Kong Stock Exchange [17]

【智通财经12月11日早间新闻精选】 1、财政部有关负责人日前表示，2025年到期续作特别国债是原特 别国债的等额滚动发行，仍与原有资产负债相对应，不增加财政赤字。 2、IMF中国事务主管索纳莉·贾 殷-钱德拉表示，IMF中国代表团成员上调今年中国经济增长预期至5%，较10月上调0.2个百分点。 3、 存储模组厂透露，目前NAND缺货程度远超过以往，多家同行手中库存仅能撑到2026年第一季度，3月 起部分厂商无货可交，第二季后缺货将成为全面现象。 4、近日，中国算力平台地方专区正式上线运 行。其中，中国算力平台（上海）率先完成与全国总平台的全体系联动，这一重要进展标志着全国一体 化算力网建设取得阶段性突破。 5、半导体设备厂商透露，台积电与日月光集团、Amkor与联电等都在 加速扩充先进封装CoWoS产能，从订单分布观察，2026-2027年GPU、ASIC客户需求均超出预期。 6、 国家药监局局长李利接受采访时表示，深化拓展临床试验审评审批、补充申请审评审批程序、分段生产 等改革试点成果，对重点品种实行"提前介入、一企一策、全程指导、研审联动"，将审评资源充分 向"全球新"的原创性产品和突破"卡脖子"技术的 ...

Industry News - The National Medical Products Administration is prioritizing the review of innovative products and domestic alternatives to critical technologies to enhance the competitiveness of China's pharmaceutical industry [4] - The Ministry of Agriculture and Rural Affairs is launching a consumption promotion activity for the New Year and Spring Festival in 2026, aiming to boost agricultural product consumption during peak seasons [5] - The NAND storage module market is experiencing significant shortages, with some manufacturers expected to run out of stock by the first quarter of 2026, leading to a nearly 50% monthly price increase for Micron's NAND products [5] - The China Computing Power Platform has officially launched, marking a significant step in the construction of a nationwide integrated computing power network [5] - Semiconductor equipment manufacturers report that TSMC and other companies are accelerating the expansion of advanced packaging capacity, with demand for GPUs and ASICs exceeding expectations for 2026-2027 [6] Company News - Kweichow Moutai announced a mid-term dividend of 30 billion yuan for 2025, with the record date set for December 18 [7] - Wuliangye announced a mid-term dividend of 10.007 billion yuan for 2025, with the record date set for December 17 [9] - Blue Si Technology plans to acquire 100% of the shares of Peimei International, a liquid cooling and server cabinet company, to expand into the AI computing infrastructure sector [10] - Huayi Brothers reported a debt default of 52.5 million yuan and plans to gradually exit and dispose of some assets [11] - Century Huatong announced that its subsidiary holds 19.5887 million shares of Moer Thread [11]